Sharmi Saha PhD
About Sharmi Saha PhD
Sharmi Saha, PhD, is a Senior Scientist I in Toxicology at CytomX Therapeutics, where she has worked since 2021. With extensive experience in nonclinical development and safety, she has contributed to advancing drug candidates through various stages of clinical trials.
Work at CytomX Therapeutics
Sharmi Saha serves as Senior Scientist I in Toxicology at CytomX Therapeutics, a position she has held since 2021. In this role, she contributes to the development and safety assessment of therapeutic candidates. Prior to this, she worked as Scientist II in Toxicology at the same company from 2018 to 2021. Her experience at CytomX Therapeutics spans a total of five years, during which she has been involved in various projects related to drug development.
Education and Expertise
Sharmi Saha earned her Doctor of Philosophy (PhD) in Chemistry, Material Science, and Tissue Engineering from the University of South Carolina, where she studied from 2007 to 2012. She completed her postdoctoral research at the University of California, San Francisco, from 2012 to 2014. Additionally, she holds a Master of Science (M.S.) in Chemistry from the Indian Institute of Technology, Roorkee, and a Bachelor of Science (B.S.) in Chemistry from Jadavpur University. Her educational background supports her expertise in toxicology and nonclinical development.
Background in Nonclinical Development
Before her tenure at CytomX Therapeutics, Sharmi Saha held several positions at Symic Bio. She worked as Senior Manager of Nonclinical Development & Safety for three months in 2018, following her role as Senior Scientist I in Nonclinical Development & Safety from 2017 to 2018. Her career at Symic Bio began as a Scientist in R&D from 2014 to 2016. Throughout her time there, she led teams focused on toxicology and safety pharmacology, advancing drug candidates through critical development phases.
Achievements in Drug Development
Sharmi Saha has played a significant role in advancing drug candidates from discovery to clinical trials. Notably, she led efforts that successfully moved two drug candidates targeting Osteoarthritis and Cardiovascular indications into Clinical Phase I/II trials within two years. She developed a screening assay for candidate selection in Osteoarthritis, achieving molecule lock within six months. Her contributions earned her recognition, including a company-wide cultural hero award at Symic Bio for her disciplined execution and efforts in building a state-of-the-art lab.
Early Career Experience
Sharmi Saha's early career includes a position as an Indian Academy of Sciences Summer Fellow at the Indian Institute of Technology, Kanpur, in 2006. She also worked as a Research Assistant at the Indian Institute of Technology, Roorkee, for three months in 2007. These early experiences laid the foundation for her subsequent academic and professional achievements in the fields of toxicology and drug development.